RLAY Insider Trading Activity and SEC Form 4 Filings
RLAY insider trading summary
Over the past 12 months, insiders at Relay Therapeutics, Inc. (RLAY) reported 34 sales worth $358.1M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $358.1M.
Latest RLAY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 28, 2026 | Donald A Bergstrom | President, R&D | Sell | $42K (2,252 @ $18.62) |
| Oct 28, 2026 | Thomas Catinazzo | Chief Financial Officer | Sell | $27K (1,469 @ $18.62) |
| Oct 28, 2026 | Peter Rahmer | See remarks | Sell | $14K (753 @ $18.62) |
| Oct 7, 2026 | Sanjiv Patel | President and CEO | Sell | $872K (48,199 @ $18.10) |
| Oct 6, 2026 | Thomas Catinazzo | Chief Financial Officer | Sell | $4K (206 @ $19.26) |
| Oct 6, 2026 | Thomas Catinazzo | Chief Financial Officer | Sell | $325K (17,511 @ $18.58) |
| Aug 26, 2026 | Peter Rahmer | See remarks | Sell | $90K (4,508 @ $20.03) |
| Aug 25, 2026 | Sb Investment Advisers (uk) Ltd | 10% Owner | Sell | $116.4M (6,000,000 @ $19.40) |
| Aug 25, 2026 | SVF Pauling (Cayman) Ltd | 10% Owner | Sell | $116.4M (6,000,000 @ $19.40) |
| Aug 25, 2026 | Softbank Vision Fund (aiv M2) L.P. | 10% Owner | Sell | $116.4M (6,000,000 @ $19.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.